Scott Yerby - Si Bone Vice President CTO
| SIBN Stock | USD 17.47 0.37 2.07% |
President
Dr. Scott A. Yerby Ph.D., is Chief Technology Officer of the Company since January 2011. He has served as our Chief Technology Officer since January 2011. Prior to joining us, Dr. Yerby served as Vice President, Research and Development for ProMed, Inc., a medical supply company, from June 2009 to January 2011. From May 2007 to June 2009, Dr. Yerby sat on the board of several nonprofit organizations. From June 2000 to May 2007, Dr. Yerby served as Vice President of Research and Development for St. Francis Medical Technologies, Inc., a spinal manufacturing company, until its acquisition by Kyphon, Inc. From June 1997 to June 2000, Dr. Yerby served as Director of Experimental Biomechanics at the Palo Alto VA Hospital. Early in his career, Dr. Yerby held appointments as Consulting Assistant Professor at Stanford University in the Department of Mechanical Engineering, Division of Biomechanical Engineering, and the Department of Functional Restoration, Division of Orthopedic Surgery since 2011.
| Age | 57 |
| Tenure | 14 years |
| Address | 471 El Camino Real, Santa Clara, CA, United States, 95050 |
| Phone | 408 207 0700 |
| Web | https://si-bone.com |
Si Bone Management Efficiency
The company has return on total asset (ROA) of (0.0956) % which means that it has lost $0.0956 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1838) %, meaning that it created substantial loss on money invested by shareholders. Si Bone's management efficiency ratios could be used to measure how well Si Bone manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of February 2025, Return On Tangible Assets is likely to drop to -0.14. In addition to that, Return On Capital Employed is likely to drop to -0.18. At this time, Si Bone's Net Tangible Assets are very stable compared to the past year. As of the 26th of February 2025, Intangibles To Total Assets is likely to grow to 0, while Other Current Assets are likely to drop about 2.6 M.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Jon Serbousek | Orthofix Medical | 63 | |
| David Bailey | Orthopediatrics Corp | 46 | |
| Tyler Lipschultz | Orthofix Medical | 58 | |
| Terence Berge | CONMED | 54 | |
| Jennifer Bolt | Integer Holdings Corp | 55 | |
| Jason Garland | Integer Holdings Corp | 50 | |
| Jim Stephens | Integer Holdings Corp | 51 | |
| Patrick Beyer | CONMED | 59 | |
| Kevin Kenny | Orthofix Medical | 59 | |
| Filippo Caldini | Establishment Labs Holdings | 59 | |
| Beau PEng | Orthofix Medical | 44 | |
| Joseph Hauser | Orthopediatrics Corp | 43 | |
| Carter Houghton | Integer Holdings Corp | 55 | |
| Shelley Thunen | Rxsight | 71 | |
| Joel Becker | Integer Holdings Corp | 53 | |
| Todd Garner | CONMED | 55 | |
| Anthony Borowicz | Integer Holdings Corp | 67 | |
| Gregory Odle | Orthopediatrics Corp | 55 | |
| Peter Shagory | CONMED | 56 | |
| Heather Cohen | CONMED | 51 | |
| Payman Khales | Integer Holdings Corp | 55 | |
Management Performance
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.0956 |
Si Bone Leadership Team
Elected by the shareholders, the Si Bone's board of directors comprises two types of representatives: Si Bone inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SIBN. The board's role is to monitor Si Bone's management team and ensure that shareholders' interests are well served. Si Bone's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Si Bone's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Saqib Iqbal, Director Relations | ||
| Anshul Maheshwari, Chief Officer | ||
| Aimee Einstein, Vice Culture | ||
| Daniel Cher, Senior Affairs | ||
| Carlton Reckling, Chief Medical Officer and Vice President Medical Affairs | ||
| Michael Pisetsky, General Counsel and Chief Compliance Officer | ||
| Laura MBA, CEO Director | ||
| Nikolas Kerr, Strategy Product | ||
| Jeffrey Dunn, Executive Chairman | ||
| Scott Yerby, Vice President CTO | ||
| Jeff Bertolini, Senior Technology | ||
| Michael JD, Secretary Officer | ||
| Joseph Powers, VP Marketing | ||
| Anthony Recupero, Chief Commercial Officer |
SIBN Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Si Bone a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.0956 | ||||
| Profit Margin | (0.18) % | ||||
| Operating Margin | (0.11) % | ||||
| Current Valuation | 620.8 M | ||||
| Shares Outstanding | 41.94 M | ||||
| Shares Owned By Insiders | 3.34 % | ||||
| Shares Owned By Institutions | 98.55 % | ||||
| Number Of Shares Shorted | 1.02 M | ||||
| Price To Book | 4.44 X |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Si Bone. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in SIBN Stock, please use our How to Invest in Si Bone guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Si Bone. If investors know SIBN will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Si Bone listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Revenue Per Share | Quarterly Revenue Growth 0.261 | Return On Assets | Return On Equity |
The market value of Si Bone is measured differently than its book value, which is the value of SIBN that is recorded on the company's balance sheet. Investors also form their own opinion of Si Bone's value that differs from its market value or its book value, called intrinsic value, which is Si Bone's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Si Bone's market value can be influenced by many factors that don't directly affect Si Bone's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Si Bone's value and its price as these two are different measures arrived at by different means. Investors typically determine if Si Bone is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Si Bone's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.